Dupilumab
(Synonyms: 度匹鲁单抗,REGN-668; SAR-231893) 目录号 : GC60798
Dupilumab（杜匹鲁单抗，REGN-668，SAR-231893）是一种对IL-4Rα具有特异性的强效全人源IgG4单克隆抗体。Dupilumab通过靶向共享受体亚基IL-4Rα阻断白细胞介素-4（IL-4）和白细胞介素-13（IL-13）介导的信号传导。
Cas No.:1190264-60-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Dupilumab (REGN-668, SAR-231893) is a potent, fully human IgG4 monoclonal antibody specific for IL-4Rα. Dupilumab blocks interleukin-4 (IL-4) and interleukin-13 (IL-13)-mediated signaling by targeting the shared receptor subunit IL-4Rα[1].
Dupilumab can inhibit intracellular STAT6 signaling induced by IL-4 and IL-13, with IC50 of 9.9 ± 2.7 ng/mL and 9.7 ± 2.5 ng/mL, respectively. Dupilumab inhibits TF-1 cell proliferation induced by cytokines IL-4 or IL-13 in a concentration-dependent manner, with IC50 of 10.8 ± 1.1 and 12.0 ± 2.4 ng/mL, respectively. When primary human peripheral blood mononuclear cells (PBMCs) are stimulated with IL-4 or IL-13 in vitro, thymus and activation-regulated chemokines(TARC) is released into the culture supernatant, and Dupilumab can inhibit the release of TARC[2].
Dupilumab effectively protects mice from house dust mite (HDM)-induced airway hyperresponsiveness (AHR). Dupilumab effectively prevents allergen-induced lung function impairment by preventing pathogenic immune cell-induced lung inflammation and IL-13-driven mucus production (GCM)[1]. Subcutaneous administration of dupilumab (25 mg/kg) to humanized IL-4/IL-4RA (B-hIL4/hIL4RA) mice improved helper T cell (Th2)-driven allergic responses. Compared with hIgG4 isotype control, Dupilumab treatment almost completely abolished the increased number of immune cells (CD45+ hematopoietic cells and eosinophils) and ovalbumin-specific IgE concentrations in the blood, as well as eosinophil infiltration in the lung tissue[2].
References:
[1] Le Floc’h A, Allinne J, Nagashima K, et al. Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation[J]. Allergy, 2020, 75(5): 1188-1204.
[2] Zhang L, Ding Y, Wang Q, et al. Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4Rα, for the treatment of Th2 inflammatory diseases[J]. Scientific Reports, 2023, 13(1): 12411.
Dupilumab（杜匹鲁单抗，REGN-668，SAR-231893）是一种对IL-4Rα具有特异性的强效全人源IgG4单克隆抗体。Dupilumab通过靶向共享受体亚基IL-4Rα阻断白细胞介素-4（IL-4）和白细胞介素-13（IL-13）介导的信号传导[1]。
Dupilumab可以抑制IL-4和IL-13诱导的细胞内STAT6信号传导，IC50分别为9.9 ± 2.7 ng/mL和9.7 ± 2.5 ng/mL。Dupilumab以浓度依赖性方式抑制细胞因子IL-4或IL-13诱导的TF-1细胞增殖，IC50分别为10.8±1.1和12.0±2.4 ng/mL。原代人外周血单核细胞（PBMCs）在体外用IL-4或IL-13刺激时，会将胸腺和激活调节趋化因子（TARC）释放到培养上清液中，Dupilumab能够抑制TARC的释放[2]。
Dupilumab有效地保护小鼠免受房尘螨（HDM）诱导的气道高反应性（AHR）。Dupilumab通过预防致病性免疫细胞诱导的肺部炎症以及IL-13驱动的粘液产生（GCM）有效防止过敏原诱导的肺功能损害[1]。人源化IL-4/IL-4RA（B-hIL4/hIL4RA）小鼠皮下给予Dupilumab（25 mg/kg），可以改善辅助型T细胞（Th2）驱动的过敏反应。与hIgG4同种型对照相比，Dupilumab处理几乎完全消除了血液中免疫细胞数量增加（CD45+造血细胞和嗜酸性粒细胞）和卵清蛋白特异性IgE浓度，以及肺组织中嗜酸性粒细胞浸润[2]。
| Cell experiment [1]: | |
Cell lines | TF-1 cell line |
Preparation Method | TF-1 cells were stimulated with IL-4 (0.5 ng/mL) or IL-13 (5 ng/mL), followed by the addition of dupilumab. CCK-8 was used to detect TF-1 cell proliferation 72 hours later. |
Reaction Conditions | 0.01 ng/ml-1 μg/ml, 72 h |
Applications | Dupilumab was able to inhibit the proliferation of TF-1 cells stimulated by IL-4 or IL-13, with IC50 valuesof 10.8 ± 1.1 and 12.0 ± 2.4 ng/mL, respectively. |
| Animal experiment [2]: | |
Animal models | Mouse models of IL-4/IL-13 and allergen-induced lung inflammation model |
Preparation Method | HDM(house dust mite )-exposed mice either received no antibody treatment, or twice-weekly subcutaneous injections of 10 or 25 mg/kg dupilumab, IL-4 Ab, mouse IL-13Rα2-Fc or a corresponding isotype control antibody (human IgG4 and mouse IgG2a) starting 3 days before the first HDM exposure. |
Dosage form | 10 or 25 mg/kg, 4 weeks,twice-weekly, s.c. |
Applications | Dupilumab effectively protects from allergen-induced lung function impairment by preventing pathogenic immune cell-induced lung inflammation as well as IL-13-driven GCM (mucus production). |
References: | |
| Cas No. | 1190264-60-8 | SDF | |
| 别名 | 度匹鲁单抗,REGN-668; SAR-231893 | ||
| Canonical SMILES | [Dupilumab] | ||
| 分子式 | 分子量 | ||
| 溶解度 | 储存条件 | Store at -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
-
Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet